A prospective study of 86 new patients with social anxiety disorder

Acta Psychiatrica Scandinavica

Volumn 103, Issue 6, 2001, Pages 447-452

  Allgulander, Christer ^a,b   Nilsson, Bo ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Anxiety disorders; Cytochrome P 450 CYP2D6; Follow up studies; Phobic disorders; Prognosis; Prospective studies; Treatment outcome

Indexed keywords

CYTOCHROME P450 2D6; PAROXETINE; PLACEBO; SEROTONIN AGONIST;

ADULT; ANORGASMIA; ANXIETY NEUROSIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DROWSINESS; DRUG EFFICACY; DRUG METABOLISM; FEMALE; FOLLOW UP; GENOTYPE; HUMAN; INTERVIEW; LASSITUDE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SEXUAL DYSFUNCTION; SOCIAL PHOBIA; TREATMENT OUTCOME;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CYTOCHROME P-450 CYP2D6; FEMALE; HUMANS; MALE; MIDDLE AGED; PAROXETINE; PATIENT COMPLIANCE; PHOBIC DISORDERS; PROGNOSIS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0035015742     PISSN: 0001690X     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0447.2001.00320.x     Document Type: Article

References (29)

1. 1. Dewit DJ, Ogborne A, Offord Dr, MacDonald K. Antecedents of the risk of recovery from DSM-III-R social phobia. Psychol Med 1999;29:569-582.
2. 2. Sutherland SM, Tupler LA, Colket JT, Davidson JRT. A 2-year follow-up of social phobia. Status after a brief medication trial. J Nerv Ment Dis 1996;184:731-738.
3. 3. Reich J, Goldenberg I, Vasile R, Goisman R, Keller M. A prospective study of the course of social phobia. Psychiatry Res 1994;54:249-258.
4. 4. Versiani M, Amrein R, Montgomery SA. Social phobia: long-term outcome and prediction of response - a moclobemide study. Int Clin Psychopharmacol 1997;12:239-254.
5. 5. Hair T, Kumar R, Rolfe TE. Maintained efficacy of paroxetine in the treatment of social anxiety disorder. American Psychiatric Association Annual Meeting, abstract no. NR656, Chicago 2000.
6. 6. Reich J, Goldenberg I, Goisman R, Vasile R, Keller M. A prospective follow-along study of the course of social phobia: II. Testing for basic predictors of course. J Nerv Ment Dis 1994;182:297-301.
7. 7. Mersch PP, Emmelkamp PM, Lips C. Social phobia: individual response patterns and the long-term effects of behavioral and cognitive interventions. A follow-up study. Behav Res Ther 1991;29:357-362.
8. 8. Stein DJ, Stein MB, Lydiard RB, Pitts CD, Oakes R, Hunter B. Predictors of response to pharmacotherapy in social anxiety disorder: an analysis of three placebo-controlled paroxetine trials. Poster, 152nd APA meeting, Washington DC 1999.
9. 9. Juster HR, Heimberg RG. Social phobia. Longitudinal course and long-term outcome of cognitive-behavioral treatment. Psychiatr Clin N Am 1995;18:821-842.
10. 10. Ameringen MV, Mancini C, Farvolden P, Oakman J. Drugs in development for social anxiety disorder: more to social anxiety than meets the SSRI. Expert Opin Invest Drugs 2000;9:2215-2231.
11. 11. Allgulander C. Paroxetine in social anxiety disorder: a randomized placebo-controlled study. Acta Psychiatr Scand 1999;100:193-198.
12. 12. Sheehan DV, Lecrubier Y, Harnett-Sheehan K et al. The Mini International Neuropsychiatric Interview (MINI): The development and validation of a structured diagnostic interview. J Clin Psychiatry 1998;59(Suppl. 20):22-33.
13. 13. Clark DB, Feske U, Masia CL et al. Systematic assessment of social phobia in clinical practice. Depr Anxiety 1997;6:47-61.
14. 14. Sheehan DV, Harnett-Sheehan K, Raj BA, The measurement of disability. Int Clin Psychopharmacol 1996;11(Suppl. 3):89-95.
15. 15. Leon AC, Olfson M, Portera L, Farber L, Sheehan DV. Assessing psychiatric impairment in primary care with the Sheehan Disability Scale. Int J Psychiatr Med 1997;27: 93-105.
16. 16. Bobes J. How is recovery from social anxiety disorder defined? J Clin Psychiatry 1998;59(Suppl. 17):12-16.
17. 17. Ballender JC, Davidson JRT, Lecrubier Y et al. Consensus statement on social anxiety disorder from the international consensus group on depression and anxiety. J Clin Psychiatry 1998;59(Suppl. 17):54-60.
18. 18. Edwards JG, Anderson I. Systematic review and guide to selection of selective serotonin reuptake inhibitors. Drugs 1999;57:507-533.
19. 19. Rosenbaum JF, Fava M, Hoog SL, Ascroft RC, Krebs WB. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry 1998;44: 77-87.
20. 20. Dahl ML, Johansson I, Palmertz MP, Ingelman-Sundberg M, Sjo̊qvist F. Analysis of the CYP2D6 gene in relation to debrisoquine and desipramine hydroxylation in a Swedish population. Clin Pharmacol Ther 1992;51:12-17.
21. 21. Alván G, Bechtel P, Iselius L, Gundert-Remy U. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 1990;39:533-537.
22. 22. Breslow NE, Day NE. Statistical methods in cancer research, vol 1. The analysis of case-control studies. Inter-national Agency for Research on Cancer Scientific Publica-tion 32. Lyons, France: International Agency for Research on Cancer, 1980.
23. 23. Kennedy SH, Eisfeld BS, Dickens SE, Bacchiochi JR, Bagby MR. Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine. J Clin Psychiatry 2000;61:276-281.
24. 24. Licinio J, Negrao AB, Prolo P, Wong M-L. Weight dysregulation: symptom and side effect. American Psychiatric Association 153rd Annual Meeting, abstract no. 105C, Chicago, 2000.
25. 25. Furmark T. Social phobia. From epidemiology to brain function. Uppsala University, Sweden, Doctoral Dissertation no. 97, Faculty of Social Sciences, 2000.
26. 26. Heimberg RG, Stein MB, Hiripi E, Kessler RC. Trends in the prevalence of social phobia in the United States: a synthetic cohort analysis of changes over four decades. Eur Psychiatry 2000;15:29-37.
27. 27. Prakash A, Foster RH. Paroxetine. A review of its use in social anxiety disorder. CNS Drugs 1999;12:151-169.
28. 28. Van Derlinden GJ, Stein DJ, Van Balkom AJ. The efficacy of the selective serotonin reuptake inhibitors (SSRIs) in social anxiety disorder (social phobia): a meta-analysis of randomized controlled trials. Int Clin Psychopharmacol 2000; 15(Suppl. 2):15-23.
29. 29. Liebowitz MR, Heimberg RG, Schneier FR et al. Cognitive-behavioral group therapy versus phenelzine in social phobia: long-term outcome. Depr Anxiety 1999;10:89-98.